Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03549338 · ClinicalTrials.gov registry record · Phase 2
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
A Phase 2 study, sponsored by Symphogen A/S.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03549338 is a Phase 2 study that was terminated before completion, run by Symphogen A/S. The registered enrollment target is 2 participants.
The verdict
NCT03549338, a Phase 2 study, was terminated before completion, sponsored by Symphogen A/S.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, open-label, 3-arm trial in the ratio of 1:1:1 to either Sym004 (Arm A) versus each of its component monoclonal antibodies (mAbs), futuximab (Arm B) or modotuximab (Arm C), in genomically-selected patients with chemotherapy-refractory metastatic colorectal carcinoma (mCRC) and acquired resistance to anti-epidermal growth factor receptor (anti-EGFR) mAb therapy. The study is designed to evaluate the relative antitumor activity of each agent as assessed by imaging studies performed after 8 weeks of treatment.
Interventions
- DRUG Sym004
- DRUG Futuximab
- DRUG Modotuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2019-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03549338
The ClinicalTrials.gov registry entry for NCT03549338 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Symphogen A/S, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sym004 is the first listed.
NCT03549338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03549338 about?
NCT03549338 is a clinical study titled "Sym004 Versus Futuximab or Modotuximab in Patients With mCRC". This is a Phase 2, randomized, open-label, 3-arm trial in the ratio of 1:1:1 to either Sym004 (Arm A) versus each of its component monoclonal antibodies (mAbs), futuximab (Arm B) or modotuximab (Arm C), in genomically-selected patients with chemotherapy-refractory metastatic colorectal carcinoma (mC...
What is the current status of trial NCT03549338?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2018-11-29. Estimated completion is 2019-03-09.
What interventions are being tested in trial NCT03549338?
The interventions under investigation include: Sym004 (DRUG), Futuximab (DRUG), Modotuximab (DRUG).
Who is sponsoring clinical trial NCT03549338?
This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.